IL302640A - Use of isatuximab for the treatment of multiple myeloma - Google Patents
Use of isatuximab for the treatment of multiple myelomaInfo
- Publication number
- IL302640A IL302640A IL302640A IL30264023A IL302640A IL 302640 A IL302640 A IL 302640A IL 302640 A IL302640 A IL 302640A IL 30264023 A IL30264023 A IL 30264023A IL 302640 A IL302640 A IL 302640A
- Authority
- IL
- Israel
- Prior art keywords
- individual
- month
- antibody
- serum
- cycles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063109305P | 2020-11-03 | 2020-11-03 | |
| US202163239108P | 2021-08-31 | 2021-08-31 | |
| PCT/US2021/072193 WO2022099257A1 (en) | 2020-11-03 | 2021-11-02 | Use of isatuximab for the treatment of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302640A true IL302640A (en) | 2023-07-01 |
Family
ID=78825149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302640A IL302640A (en) | 2020-11-03 | 2021-11-02 | Use of isatuximab for the treatment of multiple myeloma |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220135696A1 (https=) |
| EP (1) | EP4240416A1 (https=) |
| JP (1) | JP2023550311A (https=) |
| AU (1) | AU2021376374A1 (https=) |
| CA (1) | CA3197381A1 (https=) |
| IL (1) | IL302640A (https=) |
| TW (1) | TW202233235A (https=) |
| WO (1) | WO2022099257A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| KR20210006321A (ko) * | 2018-01-12 | 2021-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 항-cd38 항체의 피하 투여 |
| US11939390B2 (en) * | 2019-01-28 | 2024-03-26 | Sanofi-Aventis U.S. Llc | Methods of treating multiple myeloma |
| WO2020212912A1 (en) * | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses |
| US20210171650A1 (en) * | 2019-05-14 | 2021-06-10 | Sanofi | Methods of administering anti-cd38 antibody |
-
2021
- 2021-11-02 IL IL302640A patent/IL302640A/en unknown
- 2021-11-02 US US17/517,567 patent/US20220135696A1/en active Pending
- 2021-11-02 CA CA3197381A patent/CA3197381A1/en active Pending
- 2021-11-02 TW TW110140853A patent/TW202233235A/zh unknown
- 2021-11-02 AU AU2021376374A patent/AU2021376374A1/en active Pending
- 2021-11-02 JP JP2023528113A patent/JP2023550311A/ja active Pending
- 2021-11-02 EP EP21820805.6A patent/EP4240416A1/en active Pending
- 2021-11-02 WO PCT/US2021/072193 patent/WO2022099257A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023550311A (ja) | 2023-12-01 |
| WO2022099257A1 (en) | 2022-05-12 |
| CA3197381A1 (en) | 2022-05-12 |
| TW202233235A (zh) | 2022-09-01 |
| EP4240416A1 (en) | 2023-09-13 |
| US20220135696A1 (en) | 2022-05-05 |
| AU2021376374A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mould et al. | Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development | |
| Mould et al. | Drug development of therapeutic monoclonal antibodies | |
| Dirks et al. | Population pharmacokinetics of therapeutic monoclonal antibodies | |
| JP7712206B2 (ja) | 多発性骨髄腫の処置方法 | |
| Li et al. | Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo | |
| CN116322769A (zh) | 用于治疗多发性骨髓瘤的方法 | |
| WO2018067819A1 (en) | Compositions and methods for treatment of cancers | |
| AU2024233563A1 (en) | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies | |
| IL301625A (en) | CD1A antibodies and their uses | |
| IL302640A (en) | Use of isatuximab for the treatment of multiple myeloma | |
| JP2019530704A (ja) | がんの処置のためのアベルマブの投与レジメン | |
| JP2025138745A (ja) | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 | |
| TW202545572A (zh) | 治療表現ceacam5的癌症之方法 | |
| US20250145701A1 (en) | Bispecific antibody and application thereof | |
| CA3245572A1 (en) | USE OF ISATUXIMAB IN COMBINATION WITH OTHER AGENTS FOR THE TREATMENT OF MULTIPLE MYELOMA | |
| CN109641053A (zh) | 给药方案 | |
| CN116761627A (zh) | 艾萨妥昔单抗用于治疗多发性骨髓瘤的用途 | |
| RU2858309C2 (ru) | Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы | |
| TWI922320B (zh) | 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 | |
| IL303350A (en) | Pharmaceutical compositions of a her2/neu antibody and use of the same | |
| RU2777363C2 (ru) | Режим дозирования авелумаба для лечения злокачественного новообразования | |
| AU2024318231A1 (en) | Treatment of atopic dermatitis | |
| WO2024112561A1 (en) | Methods for the treatment of myasthenia gravis | |
| JP2026513770A (ja) | 抗ｃｔｌａ４抗体を使用して黒色腫を治療する方法 | |
| IL324392A (en) | Antibodies targeting human leukocyte antigen cathepsin g peptide complex |